Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Namur – page 13

160 clinical trials in Namur, Belgium across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Namur at a glance
160
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

160 trials in Namur

Open in trial search

Cervix carcinoma

Not recruiting

Study Comparing Tisotumab Vedotin with Chemotherapy for Patients with Recurrent or Metastatic Cervical Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:Seagen Inc.

Myelodysplastic syndrome

Not recruiting

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Rectal cancer stage III+1

Not recruiting

Study Comparing Short-Course Radiotherapy and Drug Combination for Older Patients with Locally Advanced Rectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Capecitabine
  • Sponsor:Institut Jules Bordet

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Colon cancer stage III+1

Not recruiting

Study on Aspirin for Preventing Recurrence and Improving Survival in Patients with Resected Colon Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Antwerp University Hospital

Dyspepsia

Not recruiting

Study on Reducing Proton Pump Inhibitor Use in Patients with Heartburn, Reflux, or Dyspepsia: Comparing On-Demand Use, Alginate Therapy, and Gradual Dose Reduction

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aluminium Oxide
  • Sponsor:UZ Leuven

Attention deficit hyperactivity disorder

Not recruiting

Study on the Safety and Effectiveness of Guanfacine Hydrochloride and Atomoxetine Hydrochloride for Children and Adolescents with ADHD Aged 6 to 17 Years

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Guanfacine
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer+2

Not recruiting

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:F. Hoffmann-La Roche AG

Hormone receptor positive breast cancer+1

Not recruiting

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Antipsychotics
  • Sponsor:Gilead Sciences Inc.

Diabetes mellitus

Not recruiting

A Study of Long-Term Safety of Teplizumab in Children and Adolescents with Recently Diagnosed Type 1 Diabetes

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Provention Bio Inc.

Endometrial cancer+2

Not recruiting

Study on Selinexor as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Selinexor
  • Sponsor:Karyopharm Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Namur

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory conditions including evaluation of vaccines against RSV, influenza, and treatments for chronic cough and asthma.

  • RSV and hMPV vaccine studies in elderly
  • High-dose influenza vaccine assessment
  • Uncontrolled asthma treatments

Research emphasizes preventive care and management of respiratory infections in vulnerable populations.

02 Oncology Research

Comprehensive studies examining new treatments for various types of cancer, with particular focus on breast, lung, and head and neck cancers.

  • Advanced breast cancer therapies
  • Non-small cell lung cancer treatments
  • Gastric cancer interventions

Trials evaluate novel therapeutic combinations and targeted treatments for specific cancer types.

03 Chronic Conditions

Investigation of treatments for various chronic diseases including kidney disease, narcolepsy, and chronic rhinosinusitis.

  • Kidney disease management
  • Sleep disorder treatments
  • Metabolic condition therapies

Focus on improving quality of life and disease management for long-term conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.